Systems biology to battle vascular disease

Nephrology Dialysis Transplantation

Volumn 25, Issue 4, 2010, Pages 1019-1022

  Dominiczak, Anna F ^a   Herget Rosenthal, Stefan ^b   Delles, Christian ^a   Fliser, Danilo ^c   Fournier, Isabelle ^d   Graber, Armin ^e   Girolami, Mark ^f   Holmes, Elaine ^g   Lang, Florian ^h   Molina, Franck ⁱ   Nicholson, Jeremy ^g   Remuzzi, Giuseppe ^j   Rossing, Peter ^k   Rudolph, Karl Lenhard ^l   Wolkenhauer, Olaf ^m   Xenarios, Ioannis ⁿ   Zubarev, Roman ^o   Zubov, Dimitry ^p   Vlahou, Antonia ^q   Schanstra, Joost P ^r,s  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Rotes Kreuz Krankenhaus   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIV LILLE   (France)

^e UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ UMR3145 CNRS Bio Rad   (France)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^k STENO DIABETES CENTER   (Denmark)

^l Institute of Virology   (Germany)

^m UNIVERSITY OF ROSTOCK   (Germany)

ⁿ SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^o KAROLINSKA INSTITUTE   (Sweden)

^p BAYER PHARMA AG   (Germany)

^q BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^r INSERM   (France)

^s UNIVERSITÉ DE TOULOUSE   (France)

more..

Author keywords

Chronic kidney disease; Diabetes; Systems biology; Vascular disease

Indexed keywords

BIOLOGICAL MARKER;

BIOINFORMATICS; BIOLOGY; COMPUTER MODEL; DATA BASE; DISEASE PREDISPOSITION; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; MASS SPECTROMETRY; NOTE; PRIORITY JOURNAL; VASCULAR DISEASE;

EID: 77950251629     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq025     Document Type: Note

References (23)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16-S23
2. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
3. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315
4. Booth GL, Kapral MK, Fung K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368: 29-36
5. Raizada V, Skipper B, Luo W, et al. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects. J Investig Med 2007; 55: 341-359
6. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016
7. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478
8. Zimmerli LU, Schiffer E, Zürbig P, et al. Urinary proteomics bio-markers in coronary artery disease. Mol Cell Proteomics 2008; 7: 290-298
9. Snell-Bergeon JK, Maahs DM, Ogden LG, et al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009; 11: 1-9
10. Dabelea D, Kinney G, Snell-Bergeon JK, et al. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 2003; 52: 2833-2839
11. Rossing K, Mischak H, Dakna M, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19: 1283-1290
12. Perco P, Wilflingseder J, Bernthaler A, et al. Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. J Cell Mol Med 2008; 12: 1177-1187
13. Wheelock CE, Wheelock AM, Kawashima S, et al. Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol Biosyst 2009; 5: 588-602
14. Bauer-Mehren A, Furlong LI, Sanz F. Pathway databases and tools for their exploitation: benefits, current limitations and challenges. Mol Syst Biol 2009; 5: 290
15. Schadt EE, Zhang B, Zhu J. Advances in systems biology are enhancing our understanding of disease and moving us closer to novel disease treatments. Genetica 2009; 136: 259-269
16. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39: 1329-1337
17. Lindon JC, Keun HC, Ebbels TM, et al. The Consortium for Metabo-nomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 2005; 6: 691-699
18. Rossing K, Mischak H, Rossing P, et al. The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008; 2: 997-1007
19. Doucet A, Overall CM. Protease proteomics: revealing protease in vivo functions using systems biology approaches. Mol Aspects Med 2008; 29: 339-358
20. Olivieri F, Lorenzi M, Antonicelli R, et al. Leukocyte telomere shortening in elderly type 2 DM patients with previous myocardial infarction. Atherosclerosis 2009; 206: 588-593
21. Carrero JJ, Stenvinkel P, Fellstrom B, et al. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med 2008; 263: 302-312
22. Jiang H, Schiffer E, Song Z, et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease 1. Proc Natl Acad Sci USA 2008; 105: 11299-11304
23. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847